An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Public ClinicalTrials.gov record NCT02431260. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Study identification
- NCT ID
- NCT02431260
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Interventions
- INCB054329 Monotherapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 13, 2015
- Primary completion
- Jan 30, 2018
- Completion
- Jan 30, 2018
- Last update posted
- Jun 13, 2019
2015 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of California, San Francisco, Medical Center at Mount Zion | San Francisco | California | 94115 | — |
| Sarah Cannon Research Institute Research Center | Denver | Colorado | 80218 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Horizon Oncology Center | Lafayette | Indiana | 47905 | — |
| John Hopkins | Baltimore | Maryland | 21287-0013 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-0021 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02431260, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2019 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02431260 live on ClinicalTrials.gov.